AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38585865 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 62
Study 38586018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal energy harvest post-MBS
Number of subjects: 67
Study 38586018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal energy harvest
Number of subjects: 67
Study 38586018 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie absorption assessment
Number of subjects: 67
Study 38586120 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of megestrol acetate (625 mg/5 mL)
Number of subjects: 54
Study 38586120 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of megestrol acetate (625 mg/5 mL)
Number of subjects: 54
Study 38586170 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (1× IFU)
Number of subjects: 30
Study 38586170 — intervention group
Group type: COMPARATOR
Intervention: Group B (4× IFU)
Number of subjects: 30
Study 38586278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory twice-weekly evaluations
Number of subjects: 305
Study 38586278 — intervention group
Group type: COMPARATOR
Intervention: Standard of care weekly clinical evaluations with ad hoc supplemental evaluations
Number of subjects: 305
Study 38586292 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Families (MCT-F)
Number of subjects: 48
Study 38586431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress 1.5 T cardiovascular magnetic resonance imaging (CMR) imaging and invasive coronary reactivity testing
Number of subjects: 118
Study 38586479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose RBT-1 (90 mg SnPP/240 mg FeS)
Number of subjects: 135
Study 38586479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose RBT-1 (45 mg SnPP/240 mg FeS)
Number of subjects: 135
Study 38586479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 38586479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose RBT-1
Number of subjects: 135
Study 38586479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose RBT-1
Number of subjects: 135
Study 38586588 — intervention group
Group type: EXPERIMENTAL
Intervention: Original health system intervention
Number of subjects: 16
Study 38586588 — intervention group
Group type: COMPARATOR
Intervention: Simplified intervention at control sites
Number of subjects: 16
Study 38586589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 200
Study 38586589 — intervention group
Group type: COMPARATOR
Intervention: Td
Number of subjects: 200
Study 38587033 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-PRP injection during surgery (5-mL dose)
Number of subjects: 96
Study 38587033 — intervention group
Group type: COMPARATOR
Intervention: Double-row suture-bridge ARCR alone
Number of subjects: 96
Study 38587056 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management neuro-rehabilitation intervention (6-8 sessions lasting 45-60 minutes over 9 months)
Number of subjects: 69
Study 38587056 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management neuro-rehabilitation intervention
Number of subjects: 69
Study 38587056 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 69
Study 38587079 — intervention group
Group type: EXPERIMENTAL
Intervention: 10E8VLS (5 mg/kg)
Number of subjects: 8
Study 38587079 — intervention group
Group type: EXPERIMENTAL
Intervention: 10E8VLS and VRC07-523LS (5 mg/kg each)
Number of subjects: 8
Study 38587119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 0
Study 38587119 — intervention group
Group type: COMPARATOR
Intervention: Conventional fortifier (CF)
Number of subjects: 0
Study 38587119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BC and CF
Number of subjects: 0
Study 38587233 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg once weekly)
Number of subjects: 616
Study 38587233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 38587237 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 6522
Study 38587237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6522
Study 38587239 — intervention group
Group type: EXPERIMENTAL
Intervention: Microaxial flow pump (Impella CP) plus standard care
Number of subjects: 355
Study 38587239 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 355
Study 38587247 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg olezarsen
Number of subjects: 66
Study 38587247 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg olezarsen
Number of subjects: 66
Study 38587247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 38587247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled olezarsen groups
Number of subjects: 66
Study 38587241 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment (metoprolol or bisoprolol)
Number of subjects: 5020
Study 38587241 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker treatment
Number of subjects: 5020
Study 38587249 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg olezarsen
Number of subjects: 154
Study 38587249 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg olezarsen
Number of subjects: 154
Study 38587249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 38587254 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (6 g, four weekly infusions)
Number of subjects: 18219
Study 38587254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18219
Study 38587254 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112
Number of subjects: 18219
Study 38587261 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding valve
Number of subjects: 716
Study 38587261 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable valve
Number of subjects: 716
Study 38587276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (E2) gel + ADT
Number of subjects: 310
Study 38587276 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 310
Study 38587276 — intervention group
Group type: COMPARATOR
Intervention: ADT-only control arm
Number of subjects: 310
Study 38587329 — intervention group
Group type: EXPERIMENTAL
Intervention: Customizable sequential digital cognitive aid (DCA) with ILCOR algorithm poster displayed on the wall
Number of subjects: 108
Study 38587329 — intervention group
Group type: COMPARATOR
Intervention: Poster cognitive aid (standard of care [SOC])
Number of subjects: 108
Study 38587333 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 3242
Study 38587333 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (control)
Number of subjects: 3242
Study 38587380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine FDC (50 mg dolutegravir and 300 mg lamivudine)
Number of subjects: 362
Study 38587380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine FDC
Number of subjects: 362
Study 38587557 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-mediated renal denervation (RDN)
Number of subjects: 301
Study 38587557 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 301
Study 38587557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study 38587645 — intervention group
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine hydrochloride 9 mg/kg (i.v.) followed by 3 mg/kg infusion via minipump
Number of subjects: 0
Study 38587645 — intervention group
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine hydrochloride 32 mg/kg oral administration
Number of subjects: 0
Study 38587643 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-pertuzumab and chemotherapy de-escalation
Number of subjects: 500
Study 38587643 — intervention group
Group type: COMPARATOR
Intervention: PET[-] patients with SUVmax < 2.5
Number of subjects: 500
Study 38587752 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID syndrome (PCS) score applied at 3 and 12 months after diagnosis.
Number of subjects: 603
Study 38587822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zerlasiran 300 mg
Number of subjects: 37
Study 38587822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zerlasiran 600 mg
Number of subjects: 37
Study 38587822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 37
Study 38587822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zerlasiran 200 mg (two doses)
Number of subjects: 37
Study 38587822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zerlasiran 300 mg (two doses)
Number of subjects: 37
Study 38587822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zerlasiran 450 mg (two doses)
Number of subjects: 37
Study 38587822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 37
Study 38587827 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI plus 3 months of mobile chat-based instant messaging support
Number of subjects: 772
Study 38587827 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI plus 3 months of mobile chat-based instant messaging support (adjusted for baseline characteristics)
Number of subjects: 772
Study 38587846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical interferon
Number of subjects: 52
Study 38587846 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 52
Study 38587852 — intervention group
Group type: EXPERIMENTAL
Intervention: Naked-eye 3-dimensional vision training (NVT) for 20 minutes daily
Number of subjects: 263
Study 38587852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vision training)
Number of subjects: 263
Study 38587852 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NVT and control
Number of subjects: 263
Study 38587881 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy plus self-monitoring (including completion of the 'in-Session Patient Affective Reactions Questionnaire' and the 'Rift In-Session Questionnaire' for 10 weeks)
Number of subjects: 475
Study 38587881 — intervention group
Group type: COMPARATOR
Intervention: Individual psychotherapy (treatment as usual, no postsession questionnaires)
Number of subjects: 475
Study 38587921 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM (10 running-based HIIT sessions, 5 × 4 min at 90%-95% maximal heart rate)
Number of subjects: 33
Study 38587921 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM + LIT (same as HSM with additional 30 min of LIT after each HIIT)
Number of subjects: 33
Study 38587921 — intervention group
Group type: COMPARATOR
Intervention: CG (regular training)
Number of subjects: 33
Study 38587995 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization
Number of subjects: 1542
Study 38587995 — intervention group
Group type: COMPARATOR
Intervention: Culprit-lesion-only PCI
Number of subjects: 1542
Study 38588025 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 1414
Study 38588025 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1414
Study 38588408 — intervention group
Group type: EXPERIMENTAL
Intervention: XRD-0394
Number of subjects: 0
Study 38588450 — intervention group
Group type: EXPERIMENTAL
Intervention: Home haemodialysis (HHD)
Number of subjects: 58984
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait/balance/functional training
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain training
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua-based training
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength/resistance training
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body training
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming
Number of subjects: 7837
Study 38588457 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility training
Number of subjects: 7837
Study 38588457 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 7837
Study 38588480 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg methylprednisolone i.v./d plus erythropoietin (33,000 IU/d) for 3 days
Number of subjects: 103
Study 38588480 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg methylprednisolone i.v./d plus placebo (saline solution) for 3 days
Number of subjects: 103
Study 38588480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (methylprednisolone with erythropoietin and placebo)
Number of subjects: 103
Study 38588529 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pacemaker (86.3% of patients)
Number of subjects: 1500
Study 38588529 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker (CRT-P) (5% of patients)
Number of subjects: 1500
Study 38588529 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (8.5% of patients)
Number of subjects: 1500
Study 38588529 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D implantation (3% of patients)
Number of subjects: 1500
Study 38588540 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 160
Study 38588540 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular Exercise (NEMEX)
Number of subjects: 160
Study 38588552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (One MORE); single session, 2 hours
Number of subjects: 0
Study 38588552 — intervention group
Group type: COMPARATOR
Intervention: Control group; not specified
Number of subjects: 0
Study 38588588 — intervention group
Group type: EXPERIMENTAL
Intervention: SER-401 + nivolumab
Number of subjects: 14
Study 38588588 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm (placebo antibiotic/placebo microbiome modulation + nivolumab)
Number of subjects: 14
Study 38588646 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT-DRRs
Number of subjects: 0
Study 38588646 — intervention group
Group type: COMPARATOR
Intervention: CT-DRRs
Number of subjects: 0
Study 38588682 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2)
Number of subjects: 467
Study 38588687 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-h per-day time-restricted eating (TRE) for 3 months
Number of subjects: 100
Study 38588687 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-h per-day time-restricted eating (TRE) for 3 months (per-protocol analysis)
Number of subjects: 100
Study 38588687 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 38588696 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant olaparib with chemotherapy
Number of subjects: 0
Study 38588696 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38588914 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset preeclampsia (N=139)
Number of subjects: 911
Study 38588914 — intervention group
Group type: COMPARATOR
Intervention: Late-onset preeclampsia
Number of subjects: 911
Study 38588926 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 220
Study 38588926 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 220
Study 38588926 — intervention group
Group type: COMPARATOR
Intervention: MAD vs CPAP
Number of subjects: 220
Study 38588927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 1910
Study 38588927 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1910
Study 38588928 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based approach
Number of subjects: 337
Study 38588928 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 337
Study 38588929 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg daily)
Number of subjects: 6522
Study 38588929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6522
Study 38589266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 197
Study 38589266 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 197
Study 38589266 — intervention group
Group type: EXPERIMENTAL
Intervention: IVP: yes
Number of subjects: 197
Study 38589266 — intervention group
Group type: COMPARATOR
Intervention: IVP: no
Number of subjects: 197
Study 38589266 — intervention group
Group type: EXPERIMENTAL
Intervention: IVPs (overall)
Number of subjects: 197
Study 38589266 — intervention group
Group type: EXPERIMENTAL
Intervention: IVPs (separate analyses for each trial arm)
Number of subjects: 197
Study 38589451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 51
Study 38589451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D testing
Number of subjects: 51
Study 38589451 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for low BMD by DXA and vitamin D supplementation
Number of subjects: 51
Study 38589451 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 51
Study 38589574 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent inhibition of oncogenic and wild-type RAS-GTP
Number of subjects: 0
Study 38589582 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (aerobic, strength, and stretching exercises) for 60 min, three times a week, during six months.
Number of subjects: 30
Study 38589582 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group).
Number of subjects: 30
Study 38589630 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin stimulation of the tongue (STC)
Number of subjects: 16
Study 38589780 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient prioritization software
Number of subjects: 1599
Study 38589780 — intervention group
Group type: COMPARATOR
Intervention: Standard dashboard (control)
Number of subjects: 1599
Study 38589856 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine, cisplatin, and nabpaclitaxel (GAP)
Number of subjects: 0
Study 38589856 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 0
Study 38589856 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with GAP
Number of subjects: 0
Study 38589860 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-fraction SABR (27 Gy in 2 fractions)
Number of subjects: 502
Study 38589860 — intervention group
Group type: COMPARATOR
Intervention: 5-fraction SABR (40 Gy in 5 fractions)
Number of subjects: 502
Study 38589875 — intervention group
Group type: EXPERIMENTAL
Intervention: rPMS + iTBS
Number of subjects: 28
Study 38589875 — intervention group
Group type: COMPARATOR
Intervention: Sham rPMS + iTBS
Number of subjects: 28
Study 38589875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 38589926 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX), 2-4 cycles before surgery and 4-6 cycles after surgery.
Number of subjects: 756
Study 38589926 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX), 8 cycles after upfront surgery.
Number of subjects: 756
Study 38589926 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX).
Number of subjects: 756
Study 38589926 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX).
Number of subjects: 756
Study 38589966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management coaching program
Number of subjects: 40
Study 38589966 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 38590093 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention
Number of subjects: 32
Study 38590283 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment using the heparin-bonded Viabahn endoprosthesis
Number of subjects: 100
Study 38590283 — intervention group
Group type: COMPARATOR
Intervention: Surgical femoropopliteal bypass
Number of subjects: 100
Study 38590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent cardiovascular disease (CVD)
Number of subjects: 3003
Study 38590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 3003
Study 38590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 3003
Study 38590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina
Number of subjects: 3003
Study 38590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial infarction
Number of subjects: 3003
Study 38590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic attack
Number of subjects: 3003
Study 38590326 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction
Number of subjects: 3003
Study 38590716 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemoradiation (CTRT) with concurrent capecitabine at 1250 mg/m2
Number of subjects: 135
Study 38590716 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 135
Study 38590716 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemoradiation (CTRT)
Number of subjects: 135
Study 38590831 — intervention group
Group type: EXPERIMENTAL
Intervention: 15g of specific collagen peptides (SCP) daily
Number of subjects: 55
Study 38590831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 55
Study 38590997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Atrial Fibrillation Convergent (HC)
Number of subjects: 153
Study 38590997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Atrial Fibrillation Convergent (HC) in LSPAF patients
Number of subjects: 153